Medicamen Biotech Limited — Board Meeting, 14-11-2024: Outcome of Board Meeting

The Board has approved the financial results for the quarter and half-year ended September 30, 2024. Key highlights include a consolidated revenue of ₹53 Cr, reflecting a growth momentum driven by strategic marketing initiatives and expansion into new markets. The company showed robust performance in its oncology division, with efforts towards regulatory approvals in the U.S. and Europe. Further investment in product registrations aims to unlock additional revenue streams, primarily targeting markets in Africa, Europe, and the U.S. The results indicate potential for sustained growth and market leadership.